GeoVax Labs (NASDAQ:GOVX) Issues Quarterly Earnings Results

GeoVax Labs (NASDAQ:GOVX) issued its earnings results on Thursday. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.49, Zacks reports. The business had revenue of $3.00 million during the quarter, compared to analyst estimates of $2.38 million.

GeoVax Labs Stock Down 12.6 %

Shares of GOVX opened at $1.11 on Friday. GeoVax Labs has a 12-month low of $1.09 and a 12-month high of $11.18. The business has a 50-day simple moving average of $1.67 and a two-hundred day simple moving average of $2.14.

Analyst Ratings Changes

Separately, D. Boral Capital restated a “buy” rating and set a $18.00 price objective on shares of GeoVax Labs in a research report on Friday. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, GeoVax Labs has a consensus rating of “Buy” and a consensus target price of $14.20.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.